Skip to content

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
  • Home
  • About
    • NIH Collaboratory
      • Coordinating Center
      • NIH Collaboratory Trials
      • Core Working Groups
      • Steering Committee
      • Distributed Research Network
      • Our Impact
    • Living Textbook
      • Table of Contents
      • How to Use This Site
  • Resources
    • Data and Resource Sharing
    • Training Resources
    • Tools for Researchers
    • Publications
    • Knowledge Repository
  • Webinar
  • Podcast
  • News
    • News Feed
    • Calendar
    • Subscribe
return to home
Subscribe to Newsletter go to twitter feed go to linkedin go to blue sky feed
Search
NIH Collaboratory
Living Textbook of
Pragmatic Clinical Trials

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
home button

Rethinking Clinical Trials

A Living Textbook of Pragmatic Clinical Trials

  • Design
    • What is a Pragmatic Clinical Trial?
    • Decentralized Pragmatic Clinical Trials
    • Developing a Compelling Grant Application
    • Experimental Designs and Randomization Schemes
    • Endpoints and Outcomes
    • Analysis Plan
    • Using Electronic Health Record Data
    • Building Partnerships and Teams to Ensure a Successful Trial
    • Intervention Delivery and Complexity
    • Patient Engagement
  • Data, Tools & Conduct
    • Assessing Feasibility
    • Acquiring Real-World Data
    • Assessing Fitness-for-Use of Real-World Data
    • Study Startup
    • Participant Recruitment
    • Monitoring Intervention Fidelity and Adaptations
    • Patient-Reported Outcomes
    • Clinical Decision Support
    • Mobile Health
    • Electronic Health Records–Based Phenotyping
    • Navigating the Unknown
  • Dissemination & Implementation
    • Data Sharing and Embedded Research
    • Dissemination Approaches for Different Audiences
    • Implementation
    • End-of-Trial Decision-Making
  • Ethics & Regulatory
    • Privacy Considerations
    • Identifying Those Engaged in Research
    • Collateral Findings
    • Consent, Disclosure, and Non-Disclosure
    • Data and Safety Monitoring
    • Ethical Considerations of Data Sharing in Pragmatic Clinical Trials
    • Ethics for AI and ML
    • IRB Responsibilities and Procedures

Monitoring for Serious Adverse Events – ARCHIVED

CHAPTER SECTIONS

ARCHIVE Data and safety monitoring


Section 5

Monitoring for Serious Adverse Events – ARCHIVED

Expand Contributors

Susan Ellenberg, PhD
Jeremy Sugarman, MD, MPH, MA
Doug Zatzick, MD

Contributing Editors
Gina Uhlenbrauck
Liz Wing, MA

In some ePCTs, serious adverse events (SAEs) such as death may be an expected outcome (eg, suicide prevention trials [Sisti et al 2018] or studies with very ill populations). As in a traditional RCT with such a population, monitoring of individual SAEs is not likely to be helpful; however, monitoring comparative rates of SAEs between treatment arms can help to ensure that the study intervention is not causing more SAEs.

Previous Section Next Section

SECTIONS

CHAPTER SECTIONS

sections

  1. Introduction – Data and Safety Monitoring ARCHIVED
  2. Which PCTs Should Have a DMC? – ARCHIVED
  3. Monitoring Protocol Adherence – ARCHIVED
  4. Data Issues With Monitoring PCTs – ARCHIVED
  5. Monitoring for Serious Adverse Events – ARCHIVED
  6. Futility Assessment V. 2 – ARCHIVED
  7. Futility Assessment – ARCHIVED
  8. Case Study: Planning for Monitoring PCTs – ARCHIVED
  9. Including Stakeholder Perspectives – ARCHIVED
  10. Special Training and Resources for DMCs of Pragmatic Trials – ARCHIVED
  11. Additional Resources – ARCHIVED

REFERENCES

back to top

Sisti DA, Joffe S. 2018. Implications of zero suicide for suicide prevention research. JAMA. 320:1633–1634. doi:10.1001/jama.2018.13083.

back to top


Version History

July 3, 2020: Minor corrections to layout and formatting (changes made by D. Seils).

December 13, 2018: Added a new reference as part of annual content update (L. Wing).

Published August 25, 2017

current section :

Monitoring for Serious Adverse Events – ARCHIVED

  1. Introduction – Data and Safety Monitoring ARCHIVED
  2. Which PCTs Should Have a DMC? – ARCHIVED
  3. Monitoring Protocol Adherence – ARCHIVED
  4. Data Issues With Monitoring PCTs – ARCHIVED
  5. Monitoring for Serious Adverse Events – ARCHIVED
  6. Futility Assessment V. 2 – ARCHIVED
  7. Futility Assessment – ARCHIVED
  8. Case Study: Planning for Monitoring PCTs – ARCHIVED
  9. Including Stakeholder Perspectives – ARCHIVED
  10. Special Training and Resources for DMCs of Pragmatic Trials – ARCHIVED
  11. Additional Resources – ARCHIVED

Citation:

Ellenberg S, Sugarman J, Zatzick D. ARCHIVE Data and safety monitoring: Monitoring for Serious Adverse Events – ARCHIVED. In: Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials. Bethesda, MD: NIH Pragmatic Trials Collaboratory. Available at: https://rethinkingclinicaltrials.org/chapters/ethics-and-regulatory/archive-data-and-safety-monitoring/monitoring-for-serious-adverse-events/. Updated July 9, 2025. DOI: 10.28929/043.

Footer Menu

  • How to Use This Site
  • About NIH Collaboratory
  • Enrollment Reporting
  • Grand Rounds
  • Funding Statement
Link to Twitter Link to LinkedIn Link to Blue Sky Link to NIH Collaboratory email

Reference in this Web site to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government or National Institutes of Health (NIH). NIH is not responsible for the contents of any “off-site” Web page referenced from this server.

Log in
Privacy Statement
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly. Site Map